Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation

Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation To the Editor: Asymptomatic carriers of human T-cell lymphotropic virus type I (HTLV-I) are considered acceptable as donors in allogeneic stem-cell transplantation for patients with adult T-cell leukemia–lymphoma (ATL).1 However, the infusion of HTLV-I–infected cells from HTLV-I–seropositive donors could lead to the development of donor-derived ATL under immunosuppressive conditions after stem-cell transplantation. Here we describe a patient in whom ATL derived from donor cells developed four months after transplantation of stem cells from a sibling with HTLV-I. A 44-year-old Japanese man with lymphoma-type ATL underwent transplantation of bone marrow from his HLA-identical brother in February 2004. The conditioning regimen included . . . http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The New England Journal of Medicine The New England Journal of Medicine

Donor-Derived T-Cell Leukemia after Bone Marrow Transplantation

The New England Journal of Medicine , Volume 354 (16): 2 – Apr 20, 2006

Loading next page...
 
/lp/the-new-england-journal-of-medicine/donor-derived-t-cell-leukemia-after-bone-marrow-transplantation-XvXeEkW0DF

References (5)

Publisher
The New England Journal of Medicine
Copyright
Copyright © 2006 Massachusetts Medical Society. All rights reserved.
ISSN
0028-4793
eISSN
1533-4406
DOI
10.1056/NEJMc053295
pmid
16625020
Publisher site
See Article on Publisher Site

Abstract

To the Editor: Asymptomatic carriers of human T-cell lymphotropic virus type I (HTLV-I) are considered acceptable as donors in allogeneic stem-cell transplantation for patients with adult T-cell leukemia–lymphoma (ATL).1 However, the infusion of HTLV-I–infected cells from HTLV-I–seropositive donors could lead to the development of donor-derived ATL under immunosuppressive conditions after stem-cell transplantation. Here we describe a patient in whom ATL derived from donor cells developed four months after transplantation of stem cells from a sibling with HTLV-I. A 44-year-old Japanese man with lymphoma-type ATL underwent transplantation of bone marrow from his HLA-identical brother in February 2004. The conditioning regimen included . . .

Journal

The New England Journal of MedicineThe New England Journal of Medicine

Published: Apr 20, 2006

There are no references for this article.